Assessment of the Burden of Small Intestinal Bacterial Overgrowth (SIBO) in Patients After Oesophagogastric (OG) Cancer Resection
By
K.-V. Savva
L. Hage
I. Belluomo
P. Gummet
P. R. Boshier
C. J. Peters
October 20, 2021
Clinical Scorecard: Evaluation of Small Intestinal Bacterial Overgrowth (SIBO) Prevalence in Patients Following Oesophagogastric Cancer Resection
At a Glance
Category Detail
Condition Small Intestinal Bacterial Overgrowth (SIBO) Key Mechanisms Altered number and type of bacteria within the small intestine, commonly occurring after gastroesophageal reconstruction Target Population Patients ≥18 years old, ≥1 year post-oesophagectomy or gastrectomy for oesophagogastric cancer, disease-free at assessment Care Setting Postoperative follow-up in gastroenterology or oncology outpatient settings
Key Highlights
High prevalence of SIBO (73.5%) detected by glucose hydrogen breath test in patients after oesophagogastric cancer resection SIBO symptoms are nonspecific and overlap with other digestive disorders, complicating clinical diagnosis Glucose hydrogen breath test has limitations including potential false negatives and positives, possibly underestimating true SIBO prevalence Guideline-Based Recommendations
Diagnosis
Use glucose hydrogen breath test (GHBT) for SIBO assessment post-OGC resection Be aware of GHBT limitations including low sensitivity and potential false positives from colonic fermentation or rapid transit Management
No specific management guidelines established; emphasize need for development of assessment and treatment protocols post-OGC surgery Monitoring & Follow-up
Monitor gastrointestinal symptoms and quality of life using validated questionnaires such as EORTC-QLQ-C30 Risks
SIBO may contribute to nonspecific symptoms including bloating and malnutrition, impacting patient quality of life Potential underdiagnosis due to limitations of breath testing methods Patient & Prescribing Data
Patients post-oesophagectomy or gastrectomy for oesophagogastric cancer, disease-free and ≥1 year post-surgery
No specific treatment data provided; study highlights need for guideline development for SIBO management in this population
Clinical Best Practices
Consider routine screening for SIBO in patients following oesophagogastric cancer resection due to high prevalence Use validated symptom and quality of life questionnaires to assess impact of SIBO on patients Interpret GHBT results cautiously given potential for false negatives and positives Recognize that SIBO symptoms are nonspecific and may overlap with other digestive conditions Advocate for research and guideline development to standardize diagnosis and management of SIBO post-OGC surgery References
